Atlas Trials

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Clinical trial NCT05123703 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05123703
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsing-remitting Multiple Sclerosis
Start date
2022-05-19
Primary completion
2025-06-09
Enrollment
188

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.